Molbio Diagnostics Limited Deploys IPO Proceeds for Automation & Bengaluru R&D Facility; Reports Q1 FY27 Results
Molbio Diagnostics Limited (NSE: MOLBIO, BSE: 544866) has outlined a relatively disciplined capital expenditure strategy for FY27, with the company indicating that its existing manufacturing capacity provides sufficient headroom for near-term volume growth.
The company is currently deploying proceeds from its recent stock-market listing toward automation initiatives and the development of an R&D facility in Bengaluru. At the same time, management said that the company does not require significant incremental capacity-related capex in the near term because existing device and test-kit utilisation remains well below full capacity.
The commentary came alongside Molbio Diagnostics’ Q1 FY27 results, where the company reported a sharp improvement in profitability and continued growth in Truenat test-kit consumption.
Molbio Diagnostics Q1 FY27 Performance
Molbio Diagnostics reported total income of ₹411.48 crore in Q1 FY27, compared with ₹100.47 crore in Q1 FY26.
EBITDA increased to ₹103.68 crore, compared with an EBITDA loss of ₹14.50 crore in the year-ago quarter. The EBITDA margin stood at 25.20%.
The company reported PAT of ₹52.74 crore, against a loss of ₹23.94 crore in Q1 FY26.
The improvement was primarily driven by higher Truenat test-kit consumption.
Truenat test-kit sales increased to 6.24 million units in Q1 FY27, compared with 0.79 million units in Q1 FY26.
Molbio Diagnostics Capex Plan: Focus on Automation and R&D
One of the most important points in the management commentary was the company’s approach to capital expenditure.
Molbio said it entered FY27 with meaningful capacity headroom, with FY26 utilisation at approximately:
- 42% for Truenat devices
- 58% for Truenat test kits
This indicates that the company can potentially increase volumes substantially using its existing capacity before requiring major additional manufacturing capacity.
Management therefore indicated that Molbio expects to pursue volume-led growth without near-term incremental capacity capex.
However, this does not mean the company has stopped investing.
Following its listing on August 17, 2026, Molbio said that deployment of the net issue proceeds is underway, with the funds being directed toward:
- Automation
- Building an R&D facility in Bengaluru
The strategy suggests that the company’s immediate investment priority is not simply adding manufacturing capacity, but improving operational efficiency and strengthening its research and development capabilities.
Why Automation Matters for Molbio
Automation could become increasingly important as Truenat test-kit volumes grow.
Higher utilisation of existing manufacturing infrastructure can potentially improve operating leverage, while automation can support greater consistency, productivity and scalability.
This is particularly relevant because management has already highlighted the relationship between higher test-kit volumes and improved profitability.
The Q1 FY27 EBITDA margin of 25.20% compared with a negative margin in Q1 FY26 demonstrates the operating leverage visible in the business.
However, investors should also note that management said the margin trajectory was partly offset by continued investments in the company’s international go-to-market build-out.
Bengaluru R&D Facility Could Support the Next Phase of Growth
The proposed Bengaluru R&D facility is another important part of Molbio’s long-term strategy.
The company has a pipeline of 34 additional assays covering 22 diseases, which management said remains on track.
Molbio currently has a broad Truenat platform covering infectious diseases, but the company is also looking to expand beyond infectious diseases into areas such as oncology and other non-communicable diseases.
A stronger R&D infrastructure could therefore support the development and commercialisation of additional assays and broaden the potential addressable market for the Truenat platform.
For investors, this makes the Bengaluru facility more than a conventional infrastructure investment. It is part of the company’s longer-term product-development strategy.
No Immediate Large Capacity Expansion Required
The most important takeaway from management’s commentary is that Molbio does not appear to need aggressive manufacturing-capacity expansion immediately.
With FY26 utilisation at 42% for devices and 58% for test kits, the company has considerable room to increase production.
This creates an opportunity for asset utilisation and operating leverage if Truenat test-kit consumption continues to rise.
In simple terms, the company can potentially grow volumes significantly before having to make substantial investments in additional manufacturing capacity.
That could help Molbio maintain a more disciplined capital-allocation approach, although future capex requirements will ultimately depend on demand growth and utilisation levels.
Truenat Consumption Remains the Key Growth Driver
Management continues to highlight test-kit consumption as the key driver of the business.
As of March 31, 2026, more than 12,500 Truenat devices had been installed across 90+ countries.
The company’s business model benefits from an expanding installed base because increased utilisation of Truenat devices can generate recurring demand for test kits.
This makes the growth in test-kit consumption particularly important for investors.
In Q1 FY27, Truenat test-kit sales reached 6.24 million units, significantly higher than 0.79 million units in Q1 FY26.
The company will therefore need to demonstrate that the sharp increase in test-kit consumption can be sustained over the full year.
International Expansion Could Increase Future Investment Requirements
Molbio is also expanding its international presence.
Management said the company is deepening its presence in Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets.
The company is also pursuing CE-IVDR regulatory approval for its CTNG test.
International expansion can provide a significant long-term growth opportunity, but it also requires investment in regulatory approvals, distribution networks, sales infrastructure, and market development.
Management specifically noted that continued investment in international go-to-market activities is currently affecting the margin trajectory.
Therefore, investors should not look at capex in isolation. Molbio’s total growth investment also includes spending associated with international expansion and commercialisation.
34 Assays Across 22 Diseases: A Major Long-Term Opportunity
Molbio’s assay pipeline is another important component of its growth strategy.
The company currently has a pipeline of 34 additional assays across 22 diseases.
The objective is to expand the Truenat platform beyond its existing infectious-disease applications and move into areas including oncology and other non-communicable diseases.
Successful development and commercialisation of these assays could increase the utilisation of the installed Truenat device base.
This is strategically important because the company does not necessarily need to deploy a new device for every additional test. Expanding the menu of tests available on the existing platform can potentially increase the economic value of the installed base.
Management Commentary: Focus on Full-Year Performance
Management also cautioned investors about the company’s quarterly revenue pattern.
Molbio described its business as having a non-linear revenue profile, meaning quarterly performance can vary significantly.
The company disclosed that export orders worth approximately ₹57 crore, originally about Q4 FY26, were deferred because of the prevailing situation in the Gulf and were subsequently recognised in Q1 FY27.
As a result, management believes investors should evaluate performance over the full financial year rather than relying solely on individual quarters.
This is an important consideration following the company’s recent listing.
What Management Is Focusing on in FY27
Based on the Q1 FY27 commentary, Molbio’s strategy can broadly be divided into five areas:
1. Increase Truenat test-kit consumption
The existing installed base provides a platform for higher recurring test-kit volumes.
2. Improve operating efficiency
Automation investments are expected to support scalability as volumes increase.
3. Strengthen R&D
The Bengaluru R&D facility is intended to support the company’s expanding assay pipeline.
4. Expand internationally
Africa, Southeast Asia and Latin America are among the company’s international focus areas, while regulatory pathways in developed markets are progressing.
5. Expand beyond infectious diseases
The company intends to use its technology platform to address oncology and other non-communicable diseases over time.
What Investors Should Watch
For investors tracking Molbio Diagnostics after its listing, several indicators will be particularly important.
Truenat test-kit volumes: Sustained growth in kit consumption will be critical for revenue growth.
Device utilisation: The company has significant capacity headroom, so rising utilisation could provide operating leverage.
EBITDA margin: Investors will need to monitor whether international expansion investments continue to weigh on margins or whether higher volumes offset those costs.
R&D pipeline: Progress on the 34 assays across 22 diseases will be important for the company’s long-term growth story.
International expansion: Revenue contribution from overseas markets will be an important indicator of the success of the company’s global strategy.
Capex execution: Investors should track how the IPO proceeds are deployed toward automation and the Bengaluru R&D facility.
Cash-flow quality: Management has specifically highlighted improving cash-flow quality as an objective as international and acquired businesses scale.
Molbio Diagnostics Capex Outlook
Molbio Diagnostics’ FY27 capex strategy appears relatively measured.
Rather than immediately undertaking large manufacturing-capacity expansion, the company plans to utilise its existing capacity more efficiently while investing in automation and R&D infrastructure.
The combination of 42% device utilisation and 58% test-kit utilisation in FY26 provides significant capacity headroom.
This could allow the company to accommodate higher volumes without a major near-term capacity expansion programme.
At the same time, the Bengaluru R&D facility and automation investments indicate that Molbio is continuing to invest for the next phase of growth.
The key question for investors will be whether these investments translate into sustained test-kit volume growth, new assays, stronger international revenues and improving cash generation.
Investor Takeaway
Molbio Diagnostics enters FY27 with a combination of strong Q1 profitability, rising Truenat test-kit consumption, substantial capacity headroom and a focused investment programme.
The company’s immediate capex priorities are automation and the Bengaluru R&D facility rather than aggressive capacity addition.
This could be positive for capital efficiency if test-kit volumes continue to grow because the company can potentially increase production from existing infrastructure before committing to large additional manufacturing investments.
However, investors should also keep an eye on the company’s non-linear quarterly revenue profile, international expansion costs, regulatory progress, and execution of the new R&D and automation initiatives.
The longer-term investment case will depend on whether Molbio can convert its installed Truenat base, expanding assay pipeline, and international footprint into sustained volume growth and stronger cash flows.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should conduct their own research and evaluate the company’s financials, valuation, risks, and prospects before making investment decisions.